On Dec. 1, Travere Therapeutics will have a new CEO for the first time in almost eight years, as Eric Dube hands the baton to ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Discover why Travere Therapeutics Inc's stock is sliding today, with insights into its recent patent news and leadership ...
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Clinical Trials Arena on MSN
Roche targets Novartis on IgAN market after Phase III win
Novartis gained approval of a drug in IgAN with the same target as Roche’s sefaxersen in 2026.
TravereTherapeutics (TVTX) said Wednesday that it received a notice of allowance from the US Patent and Trademark Office for ...
Ligand Pharmaceuticals agreed to provide up to $47 million in financing to AvenCell Therapeutics to support oncology drug ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Ligand Pharmaceuticals (LGND) said Thursday it agreed to provide up to $47 million to AvenCell Therapeutics to support development of its cell therapy programs. Ligand said it wil ...
The US Food and Drug Administration (FDA) has approved Mirum Pharmaceuticals’ Atebrioz (zilurgisertib) tablets to reduce the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results